1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. SHP2
  4. SHP2 Inhibitor

SHP2 Inhibitor

SHP2 Inhibitors (59):

Cat. No. Product Name Effect Purity
  • HY-100388
    SHP099
    Inhibitor 99.80%
    SHP099 is a potent, selective, orally available SHP2 inhibitor with an IC50 of 70 nM.
  • HY-136173
    Batoprotafib
    Inhibitor 99.43%
    Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.
  • HY-B0183
    Ellagic acid
    Inhibitor 99.23%
    Ellagic acid is a natural antioxidant, and acts as a potent and ATP-competitive inhibitor of CK2 and SHP2, with an IC50 of 40 nM and a Ki of 20 nM.
  • HY-116009
    RMC-4550
    Inhibitor 99.32%
    RMC-4550 is a potent, selective and allosteric inhibitor of SHP2, with an IC50 of 0.583 nM.
  • HY-141523
    Vociprotafib
    Inhibitor 99.19%
    Vociprotafib (RMC-4630) is a SHP2 inhibitor, a phosphatase whose inhibition blocks activation of the RAS-RAF-MEK-ERK signaling pathway. Vociprotafib has antitumor activity.
  • HY-157318
    PB17-026-01
    Inhibitor
    PB17-026-01 is a potent SHP2 allosteric inhibitor and shows the highest inhibitory activity with an IC50 value of 38.9?nM. PB17-026-01 can be used for the research of tumor.
  • HY-149607
    SHP2-IN-22
    Inhibitor
    SHP2-IN-22 is SHP2 allosteric inhibitor with an IC50 value of 17.7 nM. SHP2-IN-22 inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 can be used for Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research.
  • HY-100388A
    SHP099 monohydrochloride
    Inhibitor 99.92%
    SHP099 hydrochloride is a potent, selective and orally available SHP2 inhibitor with an IC50 of 70 nM.
  • HY-18756
    NSC-87877
    Inhibitor ≥99.0%
    NSC-87877 is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC50 values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).
  • HY-112368
    PHPS1
    Inhibitor 99.97%
    PHPS1 is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.
  • HY-100595
    Sodium stibogluconate
    Inhibitor 98.27%
    Sodium stibogluconate (Stibogluconate trisodium nonahydrate) is a potent inhibitor of protein tyrosine phosphatase. Sodium stibogluconate inhibits 99% of SHP-1, SHP-2 and PTP1B activity at 10, 100, 100 μg/mL, respectively.
  • HY-137092
    IACS-13909
    Inhibitor 99.97%
    IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers.
  • HY-134885
    RMC-0331
    Inhibitor 98.96%
    RMC-0331 (RM-023) is a potent, selective and orally bioavailable SOS1 inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction.
  • HY-144903
    Migoprotafib
    Inhibitor 98.06%
    Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor.
  • HY-101964
    SPI-112
    Inhibitor
    SPI-112 is a potent, selective and competitive SHP2 (PTPN11) inhibitor with IC50s of 1 μM, 18.3 μM and 14.5 μM for SHP2, protein tyrosine phosphatase (PTP) and PTP1B, respectively.
  • HY-108944
    LYP-IN-1
    Inhibitor 99.78%
    LYP-IN-1 is a potent, selective and specific LYP inhibitor with a Ki and an IC50 of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC50=5 μM) and SHP2 (IC50=2.5 μM). LYP-IN-1 exhibits highly efficacious cellular activity in T- and mast cells. LYP-IN-1 can be used for the study of autoimmune disorders. LYP-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-153740
    PF-07284892
    Inhibitor 99.63%
    PF-07284892 (ARRY-558) is a potent and orally active SHP2 inhibitor with an IC50 value of 21 nM. PF-07284892 decreases the expression of pERK.
  • HY-131132A
    JAB-3068 hydrochloride
    Inhibitor 98.74%
    JAB-3068 (SHP2-IN-6) hydrochloride is a potent SHP2 inhibitor with an IC50 of 25.8 nM. JAB-3068 hydrochloride is extracted from patent WO2017211303A1, compound 7.
  • HY-115925
    SHP2-IN-9
    Inhibitor 98.68%
    SHP2-IN-9 is a specific SHP2 inhibitor (IC50 =1.174 μM) with enhanced blood–brain barrier penetration. SHP2-IN-9 shows 85-fold more selective for SHP2 than SHP1. SHP2-IN-9 inhibits SHP2-mediated cell signal transduction and cancer cell proliferation, and inhibits the growth of cervix cancer tumors and glioblastoma growth in vivo.
  • HY-114397
    SHP394
    Inhibitor 99.41%
    SHP394 is an orally active, selective and allosteric inhibitor of SHP2, with an IC50 of 23 nM.